



# First Quarter Results Fiscal Year 2016

February 3, 2016

## Forward-Looking Statements

- These materials include forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first quarter earnings release and in our recent SEC filings

## Non-GAAP Financial Measures

- These materials also include Non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found herein, or in our earnings release and the financial schedules attached thereto.
- **A copy of the press release, including the financial schedules, is posted on the "Investors" section of the BD.com website.**

## Non-GAAP Financial Measures

- Certain financial information excludes the impact of the following items:
  1. Foreign currency translation.
  2. All adjustments to current and prior year as noted on the "Adjustment Reconciliation" schedules in the appendix of this presentation, including deferred revenue adjustments associated with the write-down of CareFusion's deferred revenue balance to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts. Revenue for these contracts is typically deferred and recognized over the term of the contracts



FXN = Estimated foreign exchange-neutral currency growth. \$ = Dollars in millions except per share data.

Comparable FXN = Estimated foreign exchange-neutral currency growth including BD and CareFusion in the current and prior year periods.

Note: All figures on accompanying slides are rounded. Totals may not add due to rounding. Percentages are based on un-rounded figures.

# Executive Overview

**Vincent A. Forlenza**

Chairman, CEO and President



# Q1 FY 2016 Business Highlights

- ◆ Solid start to fiscal year 2016
- ◆ Performance from both segments driving in-line revenues and earnings better than our expectations
  - ◆ First quarter margin improvement of +220 bps driven by operational efficiencies and cost synergies
- ◆ Strategic review process continues
  - ◆ Adding IV Solutions to Medication Management portfolio
- ◆ Maintain currency-neutral revenue guidance
- ◆ Maintain adjusted EPS guidance range and raising currency-neutral earnings expectations

# Q1 FY 2016 Financial Highlights

	First Quarter			
As Adjusted	\$	Growth %	FXN Growth%	Comparable FXN Growth%
Revenues	\$2,992	45.9%	53.8%	1.8%
EPS	\$1.96	28.1%	45.8%	N/A

- ◆ First quarter revenue growth of 1.8% FXN due to anticipated tough comparisons over prior year
- ◆ Underlying margin improvement of +220 bps
- ◆ Strong first quarter EPS of \$1.96

# Financial Update

**Christopher Reidy**

Chief Financial Officer and  
Executive Vice President of Administration



# FY 2016 Adjusted Revenues by Segment

As Adjusted	First Quarter			
	\$	Growth %	FXN Growth%	Comparable FXN Growth%
<b>Total Revenues</b>	<b>\$2,992</b>	<b>45.9%</b>	<b>53.8%</b>	<b>1.8%</b>
Medical	2,060	92.1%	101.4%	1.9%
Life Sciences	933	(4.8%)	1.7%	1.7%

# FY 2016 Adjusted U.S. and International Revenues

As Adjusted	First Quarter			
	\$	Growth %	FXN Growth%	Comparable FXN Growth%
<b>U.S.</b>	<b>\$1,697</b>	<b>92.6%</b>	<b>92.6%</b>	<b>1.5%</b>
Medical	1,272	178.1%	178.1%	1.9%
Life Sciences	425	0.3%	0.3%	0.3%
<b>International</b>	<b>\$1,295</b>	<b>10.7%</b>	<b>24.6%</b>	<b>2.2%</b>
Medical	788	28.2%	44.4%	1.9%
Life Sciences	508	(8.6%)	2.7%	2.7%



# FY 2016 Developed & Emerging Markets

As Adjusted	First Quarter		
	\$	Comparable FXN Growth %	% of BD Revenues
Developed Markets	\$2,527	1.7%	84%
Emerging Markets	\$465	2.4%	16%
China	\$163	4.5%	5%



# FY 2016 Safety Revenues

	First Quarter			
	\$	Growth %	FXN Growth %	Comparable FXN Growth %
<b>Total Safety</b>	<b>\$737</b>	<b>28.6%</b>	<b>35.3%</b>	<b>4.9%</b>
<b>By Geography</b>				
U.S.	447	44.9%	44.9%	3.8%
International	290	9.5%	24.1%	6.5%
<b>By Segment</b>				
Medical	467	57.9%	64.5%	5.4%
Life Sciences	270	(2.7%)	4.1%	4.1%

- ◆ Emerging Markets Safety grew 10.9% in Q1




# Q1 FY 2016 Adjusted Income Statement

	Favorable (Unfavorable)				
	Adjusted Q1 FY 2016	Adjusted Q1 FY 2015	\$ Change	% Change	FXN % Change
Revenues <b>Comparable basis</b>	\$2,992	\$2,051	\$941	45.9%	53.8% <b>1.8%</b>
Gross Profit	1,566	1,063	503	47.3%	57.9%
% of Revenues <b>Comparable basis</b>	52.3%	51.8% <b>51.9%</b>			<b>3.6%</b>
SSG&A	745	532	(213)	(40.0%)	(47.3%)
% of Revenues <b>Comparable basis</b>	24.9%	25.9% <b>26.0%</b>			<b>3.5%</b>
R&D	187	129	(58)	(45.1%)	(47.6%)
% of Revenues <b>Comparable basis</b>	6.3%	6.3% <b>5.7%</b>			<b>(6.2%)</b>
Operating Income	634	402	232	57.6%	75.2%
% of Revenues <b>Comparable basis</b>	21.2%	19.6% <b>20.2%</b>			<b>12.0%</b>
Tax Rate	21.5%	21.0%			
<b>Adjusted EPS</b>	<b>\$1.96</b>	<b>\$1.53</b>	<b>\$0.43</b>	<b>28.1%</b>	<b>45.8%</b>


# Q1 FY 2016 Adjusted Margin Changes Year-Over-Year

- Building off strong momentum of ~100 bps<sup>(1)</sup> underlying operating margin expansion in FY 2015

## Gross Profit (% of sales)



## Operating Margin (% of sales)



(1) ~100 bps underlying margin expansion excludes currency and pension impacts.  
 Note: Q1 2015 Comparable Basis includes Adjusted CareFusion prior year results for reporting changes for comparable basis.

# Guidance


**Christopher Reidy**

Chief Financial Officer

Executive Vice President of Administration



# FY 2016 Adjusted EPS Guidance



**Maintain \$8.37 to \$8.44  
Adjusted EPS Guidance Range**



# FY 2016 Guidance

As Adjusted	November Guidance	February Update
<b>Total Revenues – FXN</b>	24.5% to 25.0%	24.5% to 25.0%
<b>Total Revenues – Rptd</b>	23.0% to 23.5%	<b>20.0% to 20.5%</b>
Medical Revenues – FXN	36.0% to 36.5%	36.0% to 36.5%
<b>Comparable Organic Total Revenues – FXN<sup>(1)</sup></b>	4.5% to 5.0%	4.5% to 5.0%
Comparable Medical Revenues – FXN <sup>(2)</sup>	4.5% to 5.0%	4.5% to 5.0%
Life Sciences Revenues – FXN	4.5% to 5.0%	<b>4.0% to 4.5%</b>
Gross Profit	52.0% to 52.5%	52.0% to 52.5%
SSG&A	24.5% to 25.0%	<b>24.0% to 24.5%</b>
R&D	~6%	<b>6.0% to 6.5%</b>
Operating Income Underlying Margin Expansion <sup>(3)</sup>	21.0% to 22.0% +130 to 150 bps	21.0% to 22.0% <b>+170 to 190 bps</b>
Effective Tax Rate	21.5% to 22.5%	<b>21.0% to 22.0%</b>
<b>EPS</b>	\$8.37 to \$8.44	\$8.37 to \$8.44
<b>EPS – FXN</b>	\$8.73 to \$8.80	<b>\$9.01 to \$9.08</b>
<b>EPS – FXN Accretion</b>	~22% Accretion	~22% Accretion
<b>EPS – FXN Growth</b>	~22% to 23%	<b>~26% to 27%</b>
Operating Cash Flow	~\$2.6B	~\$2.6B
Capital Expenditures	~\$650-700M	~\$650-700M
Interest/Other, net	~(\$400M)	~(\$400M)
Share Count	~217M	~217M

Note: Guidance updates denoted in bold.



(1) Excludes the impact from a distribution agreement change in the Respiratory Solutions business and non-annualized acquisitions.

(2) Excludes the impact from a distribution agreement change in the Respiratory Solutions business.

(3) Underlying Margin Expansion excludes currency and pension impacts.

# Executive Overview

**Vincent A. Forlenza**

Chairman, CEO and President





# Q1 FY2016 Business Update: Growth and Strategic Initiatives

## New Product Innovation



- Launched FACSSymphony (X-50) multi-parameter instrument to early access customers
- Launched FACSCelesta
- BD MAX™ menu expansion continues in FY16

## Strategic / Business Initiatives



- Divested BD Simplist, Adding IV Solutions
- Strategic review process continues
- New brand launch: “Advancing the World of Health”

## Partnerships / Collaborations



- On-track for mid-FY16 launch of insulin infusion sets
- Continued adoption of BD Bruker Maldi Biotyper globally




# Q1 FY2016 Business Update: Operational Efficiencies

## Operational Efficiencies



- G&A functional transformation continued in first quarter
- Harmonizing IT infrastructure
- On-track to achieve FY16 cost synergies
- Sustained lower oil prices benefitting raw material costs

## Operating Margin Expansion (FXN)



# Key Takeaways

- ◆ First quarter indicates a solid start to FY 2016
- ◆ Medical and Life Sciences segments continued to perform well
- ◆ Significant operational efficiencies evident in margin expansion
- ◆ Maintain currency-neutral revenue guidance
- ◆ Maintain adjusted EPS guidance range and raising currency-neutral earnings expectations

Advancing  
the World  
of Health



# Q1 FY 2016 & Q1 FY 2015 Adjustment Reconciliations

(Unaudited; Amounts in millions, except per share data)

	Three Months Ended December 31, 2015										
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisition-related Cost	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share
<b>Reported \$ for Three Months Ended December 31, 2015</b>	<b>\$ 2,986</b>	<b>\$ 1,408</b>	<b>\$ 748</b>	<b>\$ 187</b>	<b>\$ 121</b>	<b>\$ 352</b>	<b>\$ (97)</b>	<b>\$ 6</b>	<b>\$ 37</b>	<b>\$ 229</b>	<b>\$ 1.06</b>
<i>Reported % of Revenues</i>		47.1%	25.1%	6.3%		11.8%				7.7%	
<i>Reported effective tax rate</i>									14.0%		
<b>Specified items:</b>											
Purchase accounting adjustments <sup>(1)</sup>	6	158	(3)	-	-	161	(8)	-	34	120	0.55
Restructuring costs <sup>(2)</sup>	-	-	-	-	(85)	85	-	-	32	53	0.25
Integration costs <sup>(2)</sup>	-	-	-	-	(35)	35	-	-	13	22	0.10
<b>Adjusted \$ for Three Months Ended December 31, 2015</b>	<b>\$ 2,992</b>	<b>\$ 1,566</b>	<b>\$ 745</b>	<b>\$ 187</b>	<b>\$ -</b>	<b>\$ 634</b>	<b>\$ (105)</b>	<b>\$ 6</b>	<b>\$ 116</b>	<b>\$ 424</b>	<b>\$ 1.96</b>
<i>Adjusted % of Revenues</i>		52.3%	24.9%	6.3%		21.2%				14.2%	
<i>Adjusted effective tax rate</i>									21.5%		
	Three Months Ended December 31, 2014										
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisition-related Cost	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share
<b>Reported \$ for Three Months Ended December 31, 2014</b>	<b>\$ 2,051</b>	<b>\$ 1,045</b>	<b>\$ 544</b>	<b>\$ 129</b>	<b>\$ 23</b>	<b>\$ 349</b>	<b>\$ (76)</b>	<b>\$ 2</b>	<b>\$ 50</b>	<b>\$ 236</b>	<b>\$ 1.20</b>
<i>Reported % of Revenues</i>		50.9%	26.5%	6.3%		17.0%				11.5%	
<i>Reported effective tax rate</i>									17.4%		
<b>Specified items:</b>											
Purchase accounting adjustments <sup>(3)</sup>	-	18	-	-	-	18	-	-	6	12	0.06
Integration costs <sup>(2)</sup>	-	-	-	-	(13)	13	-	-	5	9	0.04
Transaction costs <sup>(2)</sup>	-	-	-	-	(10)	10	-	-	-	10	0.05
Financing costs <sup>(2)</sup>	-	-	-	-	-	-	44	-	16	28	0.14
Litigation-related Charge <sup>(4)</sup>	-	-	(12)	-	-	12	-	-	4	7	0.04
<b>Adjusted \$ for Three Months Ended December 31, 2014</b>	<b>\$ 2,051</b>	<b>\$ 1,063</b>	<b>\$ 532</b>	<b>\$ 129</b>	<b>\$ -</b>	<b>\$ 402</b>	<b>\$ (32)</b>	<b>\$ 2</b>	<b>\$ 80</b>	<b>\$ 302</b>	<b>\$ 1.53</b>
<i>Adjusted % of Revenues</i>		51.8%	25.9%	6.3%		19.6%				14.7%	
<i>Adjusted effective tax rate</i>									21.0%		
Three Months Ended December 31, 2015 versus December 31, 2014											
<b>Adjusted \$ change</b>	<b>\$ 941</b>	<b>\$ 503</b>	<b>\$ (213)</b>	<b>\$ (58)</b>	<b>\$ -</b>	<b>\$ 232</b>	<b>\$ (73)</b>	<b>\$ 3</b>	<b>\$ (36)</b>	<b>\$ 122</b>	<b>\$ 0.43</b>
<b>Adjusted % change</b>	<b>45.9%</b>	<b>47.3%</b>	<b>(40.0%)</b>	<b>(45.1%)</b>	<b>-</b>	<b>57.6%</b>	<b>NM</b>	<b>NM</b>	<b>(44.6%)</b>	<b>40.3%</b>	<b>28.1%</b>
<b>Foreign currency translation impact</b>	<b>\$ (162)</b>	<b>\$ (113)</b>	<b>\$ 39</b>	<b>\$ 3</b>	<b>\$ -</b>	<b>\$ (71)</b>	<b>\$ -</b>	<b>\$ (4)</b>	<b>\$ 16</b>	<b>\$ (58)</b>	<b>\$ (0.27)</b>
<b>Adjusted foreign currency neutral \$ change</b>	<b>\$ 1,103</b>	<b>\$ 616</b>	<b>\$ (252)</b>	<b>\$ (61)</b>	<b>\$ -</b>	<b>\$ 302</b>	<b>\$ (73)</b>	<b>\$ 7</b>	<b>\$ (52)</b>	<b>\$ 180</b>	<b>\$ 0.70</b>
<b>Adjusted foreign currency neutral % change</b>	<b>53.8%</b>	<b>57.9%</b>	<b>(47.3%)</b>	<b>(47.6%)</b>	<b>-</b>	<b>75.2%</b>	<b>NM</b>	<b>NM</b>	<b>(65.1%)</b>	<b>59.5%</b>	<b>45.8%</b>

<sup>(1)</sup> Represents non-cash amortization expense of \$150 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$3 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.

<sup>(2)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(3)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

<sup>(4)</sup> Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

NM - Not Meaningful



# Q1 FY 2016 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

(Unaudited)

	Three Months Ended December 31,						
	2015	2014	Growth	Foreign Currency Translation	Foreign Currency Neutral Growth	Growth %	Foreign Currency Neutral Growth %
<b>Reported Diluted Earnings per Share</b>	<b>\$ 1.06</b>	<b>\$ 1.20</b>	<b>\$ (0.14)</b>	<b>\$ (0.26)</b>	<b>\$ 0.12</b>	<b>(11.7%)</b>	<b>10.0%</b>
Purchase Accounting Adjustments (\$153 million or \$120 million after-tax and \$18 million or \$12 million after-tax, respectively)	0.55 <sup>(1)</sup>	0.06 <sup>(2)</sup>					
Restructuring Costs (\$85 million or \$53 million after-tax) <sup>(3)</sup>	0.25	-					
Integration Costs (\$35 million or \$22 million after-tax and \$13 million or \$9 million after-tax, respectively) <sup>(3)</sup>	0.10	0.04					
Transaction Costs (\$10 million or \$10 million after-tax) <sup>(3)</sup>	-	0.05					
Financing Costs (\$44 million or \$28 million after-tax) <sup>(3)</sup>	-	0.14					
Litigation-related Charge (\$12 million or \$7 million after-tax) <sup>(4)</sup>	-	0.04					
<b>Adjusted Diluted Earnings per Share</b>	<b>\$ 1.96</b>	<b>\$ 1.53</b>	<b>\$ 0.43</b>	<b>\$ (0.27)</b>	<b>\$ 0.70</b>	<b>28.1%</b>	<b>45.8%</b>

<sup>(1)</sup> Represents non-cash amortization expense of \$150 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$3 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.

<sup>(2)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

<sup>(3)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(4)</sup> Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.



# FY 2016 Reconciliation – FX Impact Emerging Markets and China

(Unaudited; Amounts in millions)

	Three Months Ended December 31,				
	As Reported		% Change		
	2015	2014	Reported	FX Neutral	FX Impact
Total Developed Markets Revenue	\$ 2,527	\$ 1,508	67.6	74.6	(7.0)
Total Emerging Markets Revenue	\$ 465	\$ 543	-14.2	-3.7	(10.5)
Total Emerging Markets Safety Revenue	\$ 100	\$ 122	-17.6	-5.3	(12.3)

	Three Months Ended December 31,				
	As Reported		% Change		
	2015	2014	Reported	FX Neutral	FX Impact
Total China Revenue	\$ 163	\$ 152	6.9	10.4	(3.5)

	Three Months Ended December 31,											
	BD Reported 2015	A BD Reported 2014	B CFN Reported 2014	C BD Adjustment 2014 *	D CFN Adjustment 2014 *	E Respiratory Adjustment ** 2014	A+C=F BD As Adjusted 2014	B+D+E=G CFN As Adjusted 2014	F+G Comparable Historical 2014	% Change		
										Adjusted Comparable	FX Neutral	FX Impact
Total Developed Markets Revenue	\$ 2,527	\$ 1,508	\$ 977	\$ 92	\$ 33	\$ (23)	\$ 1,600	\$ 988	\$ 2,588	-2.4	1.7	-4.1
Total Emerging Markets Revenue	\$ 465	\$ 543	\$ 92	\$ (92)	\$ (33)	n/a	\$ 451	\$ 59	\$ 510	-8.7	2.4	-11.2
Total Emerging Markets Safety Revenue	\$ 100	\$ 122	\$ 19	\$ (23)	\$ (14)	n/a	\$ 99	\$ 5	\$ 104	-3.6	10.9	-14.4

	Three Months Ended December 31,						
	BD Reported 2015	A BD Reported 2014	B CFN Reported 2014	A+B Comparable Historical 2014	% Change		
					Comparable	FX Neutral	FX Impact
Total China Revenue	\$ 163	\$ 152	\$ 9	\$ 161	1.1	4.5	-3.3

\* Emerging market revenues in the first quarter of fiscal year 2015 have been revised to reflect a first quarter fiscal year 2016 change in the composition of countries we define as emerging markets within the Asia Pacific region.

\*\* To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.



# FY 2016 Comparable Margin Reconciliation

(Unaudited; Amounts in millions)

Three Months Ended December 31, 2015					
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income
<b>Adjusted \$ for Three Months Ended December 31, 2015</b>	<b>A \$ 2,992</b>	<b>\$ 1,566</b>	<b>\$ 745</b>	<b>\$ 187</b>	<b>\$ 634</b>
<i>Adjusted % of Adjusted Revenues</i>		52.3%	24.9%	6.3%	21.2%
Three Months Ended December 31, 2014					
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income
<b>BD Standalone for Three Months Ended December 31, 2014</b>	<b>\$ 2,051</b>	<b>\$ 1,045</b>	<b>\$ 544</b>	<b>\$ 129</b>	<b>\$ 349</b>
<i>Reported % of Revenues</i>		50.9%	26.5%	6.3%	17.0%
<b>Specified items:</b>					
Purchase accounting adjustments <sup>(1)</sup>	-	18	-	-	18
Integration costs <sup>(2)</sup>	-	-	-	-	13
Transaction costs <sup>(2)</sup>	-	-	-	-	10
Litigation-related Charge <sup>(3)</sup>	-	-	(12)	-	12
<b>BD Standalone Adjusted for Three Months Ended December 31, 2014</b>	<b>B \$ 2,051</b>	<b>\$ 1,063</b>	<b>\$ 532</b>	<b>\$ 129</b>	<b>\$ 402</b>
<i>Adjusted % of Reported Revenues</i>		51.8%	25.9%	6.3%	19.6%
<b>CareFusion Reported for Three Months Ended December 31, 2014</b>	<b>\$ 1,069</b>	<b>\$ 535</b>	<b>\$ 279</b>	<b>\$ 49</b>	<b>\$ 178</b>
<i>Reported % of Revenues</i>		50.0%	26.1%	4.6%	16.6%
<b>Specified items:</b>					
Restructuring and Acquisition Integration <sup>(4)</sup>	-	-	-	-	32
Amortization of Acquired Intangibles <sup>(5)</sup>	-	-	(19)	-	19
P&L Line Reclassifications <sup>(6)</sup>	-	23	20	1	(2)
Respiratory Adjustment <sup>(7)</sup>	(23)	-	-	-	-
<b>CareFusion Adjusted for Three Months Ended December 31, 2014</b>	<b>C \$ 1,046</b>	<b>\$ 558</b>	<b>\$ 280</b>	<b>\$ 50</b>	<b>\$ 227</b>
<i>Adjusted % of Reported Revenues</i>		52.1%	26.2%	4.7%	21.2%
<b>Comparable Adjusted for Three Months Ended December 31, 2014</b>	<b>D=B+C \$ 3,098</b>	<b>\$ 1,621</b>	<b>\$ 812</b>	<b>\$ 179</b>	<b>\$ 629</b>
<i>Adjusted % of Reported Revenues</i>		51.9%	26.0%	5.7%	20.2%
Three Months Ended December 31, 2015 versus December 31, 2014					
<b>Comparable adjusted \$ change</b>	<b>E=A-D \$ (105)</b>	<b>\$ (55)</b>	<b>\$ 67</b>	<b>\$ (8)</b>	<b>\$ 5</b>
<b>Comparable adjusted % change</b>	<b>F=E/D (3.4%)</b>	<b>(3.4%)</b>	<b>8.3%</b>	<b>(4.4%)</b>	<b>0.7%</b>
<b>Comparable foreign currency translation impact</b>	<b>G \$ (162)</b>	<b>\$ (113)</b>	<b>\$ 39</b>	<b>\$ 3</b>	<b>\$ (71)</b>
<b>Comparable adjusted foreign currency neutral \$ change</b>	<b>H=E-G \$ 57</b>	<b>\$ 58</b>	<b>\$ 28</b>	<b>\$ (11)</b>	<b>\$ 75</b>
<b>Comparable adjusted foreign currency neutral % change</b>	<b>I=H/D 1.8%</b>	<b>3.6%</b>	<b>3.5%</b>	<b>(6.2%)</b>	<b>12.0%</b>

<sup>(1)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

<sup>(2)</sup> Represents integration and transaction costs associated with the CareFusion acquisition.

<sup>(3)</sup> Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

<sup>(4)</sup> Represents restructuring and acquisition integration charges primarily related to transaction costs, integration planning expenses and other charges associated with the company's proposed merger with Becton, Dickinson and Company, as provided by CareFusion management.

<sup>(5)</sup> Represents non-cash expense associated with amortization of identifiable intangible assets of acquired businesses, as provided by CareFusion management.

<sup>(6)</sup> Represents the reclassification of CareFusion P&L line items to align with BD.

<sup>(7)</sup> Represents the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.





# FY 2016 Outlook Reconciliation

	FY2016 Outlook		
	Revenues	FX Impact	FXN Basis
Full Year FY2016 Estimated Growth on a Reported Basis	20.0% - 20.5%	~(4.5%)	24.5% - 25.0%
Deferred Revenue Adjustment	NM	NM	NM
Adjusted Full Year FY2016 Estimated Growth	20.0% - 20.5%	~(4.5%)	24.5% - 25.0%
	Full Year FY2016 (estimated)	Full Year FY2015	% Increase
Reported Fully Diluted Earnings per Share	\$ 6.23 - 6.30	\$ 3.35	NM
Purchase Accounting Adjustments	1.79	2.17	
Restructuring Costs	0.25 <sup>(1)</sup>	0.80	
Integration Costs	0.10 <sup>(1)</sup>	0.29	
Transaction Costs	-	0.19	
Financing Costs	-	0.31	
Litigation-related Charge	-	0.04	
Employee Termination Cost-related Amounts	-	(0.01)	
Dilutive Share Impact	-	0.02	
Adjusted Fully Diluted Earnings per Share	<u>\$ 8.37 - 8.44</u>	<u>\$ 7.16</u>	17.0% - 18.0%
FX Impact	<u>\$ (0.64)</u>		<u>(9.0%)</u>
Adjusted Fully Diluted Earnings per Share, FXN	<u>\$ 9.01 - 9.08</u>		<u>26.0% - 27.0%</u>

NM - Not Meaningful

FXN = Foreign Currency Neutral

<sup>(1)</sup> FY2016 restructuring and integration costs reflect year-to-date realized costs.



# FY 2016+ Product Launches

Medical Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> <li>• BD Insulin Infusion Sets</li> <li>• Pyxis Mini</li> </ul>	<ul style="list-style-type: none"> <li>➤ FY 2016</li> <li>➤ FY 2016</li> </ul>
Life Sciences Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> <li>• BD MAX™ – Extended Enteric Bacterial</li> <li>• BD MAX™ – Enteric Viral</li> <li>• BD MAX™ – GC/CT and GC/CT/Trich</li> <li>• BD MAX™ – Vaginitis / Vaginosis</li> <li>• BD Veritor™ – Next Generation</li> <li>• BD Totalys™</li> <li>• BD Horizon™ (Sirigen) Dyes</li> <li>• BD FACSCelesta</li> <li>• BD FACSseq</li> <li>• BD Clic LP</li> <li>• BD Barricor™</li> <li>• BD UltraTouch™ PBBCS</li> </ul>	<ul style="list-style-type: none"> <li>➤ FY 2016 EU / FY 2017 U.S.</li> <li>➤ FY 2017 EU (Delay) / FY 2017 U.S.</li> <li>➤ FY 2016 U.S.</li> <li>➤ FY 2016 EU / U.S.</li> <li>➤ FY 2016</li> <li>➤ FY 2016 U.S.</li> <li>✓ Q1 FY 2016</li> <li>✓ 1H FY 2016</li> <li>➤ FY 2016</li> <li>➤ FY 2016</li> <li>➤ FY 2016</li> <li>➤ FY 2016</li> </ul>

